8-K: Regeneron Reports Mixed Q4 Results, Highlights Pipeline Progress and Strategic Acquisitions

Regeneron's fourth-quarter revenue saw a modest 1% increase, but excluding Ronapreve, revenue grew by 14%, with significant advancements in their pipeline and strategic acquisitions.

Summary

• Regeneron Pharmaceuticals reported a 1% increase in fourth-quarter 2023 revenues to $3.43 billion compared to the same period in 2022, however, excluding Ronapreve, revenues increased by 14%.
• Full-year 2023 revenues increased by 8% to $13.12 billion, and excluding Ronapreve, revenues increased by 12%.
• Dupixent global net sales, recorded by Sanofi, increased by 31% in the fourth quarter to $3.22 billion and 33% for the full year to $11.59 billion.
• U.S. net sales for EYLEA HD and EYLEA were $1.46 billion in the fourth quarter, including $123 million from EYLEA HD, and $5.89 billion for the full year, including $166 million from EYLEA HD.
• Libtayo global net sales increased by 44% in the fourth quarter to $244 million and 50% for the full year to $869 million.
• GAAP diluted EPS was $10.19 and non-GAAP diluted EPS was $11.86 for the fourth quarter, which includes an unfavorable $0.21 impact from an acquired IPR&D charge.
• The company submitted a sBLA for Dupixent in COPD and a BLA for linvoseltamab in multiple myeloma to the FDA.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong growth in key products and pipeline advancements, but tempered by lower overall revenue growth and decreased GAAP earnings. The strategic acquisition is a positive sign, but the company faces risks and challenges.

Positives

• Excluding Ronapreve, revenue growth was strong at 14% for the quarter and 12% for the full year.
• Dupixent and Libtayo showed significant sales growth, indicating strong market demand.
• EYLEA HD is gaining traction with $123 million in sales in its first full quarter.
• The company is actively advancing its pipeline with multiple regulatory submissions.
• Strategic acquisition of 2seventy bio's cell therapy pipeline expands Regeneron's portfolio.
• The company has received multiple regulatory approvals for EYLEA HD and Dupixent in various regions and indications.
• The company has a strong share repurchase program with $1.5 billion remaining.

Negatives

• Overall revenue growth was only 1% for the quarter, indicating a slowdown when including Ronapreve.
• GAAP net income and EPS decreased for both the quarter and the full year.
• EYLEA sales decreased due to changing market dynamics and the launch of EYLEA HD.
• GAAP and non-GAAP R&D expenses increased due to higher headcount and pipeline advancement costs.
• GAAP and non-GAAP SG&A expenses increased due to higher headcount and commercialization costs.

Risks

• The company faces competition from other drugs and product candidates.
• Regulatory approvals and commercial launches may be delayed or unsuccessful.
• The company's financial projections and guidance are subject to change.
• The company's reliance on collaborators and third parties for manufacturing and supply chains poses a risk.
• The company is involved in ongoing patent litigation and other legal proceedings.
• The company's business is subject to the impact of public health outbreaks and pandemics.

Future Outlook

Regeneron plans to build on its momentum in 2024 with continued growth of Dupixent and EYLEA HD, bringing new therapies to market, and advancing its pipeline. The company also plans to invest heavily in internal R&D, drive commercial execution, and deploy capital to business development and share repurchases.

Management Comments

• 2023 marked another year of exceptional accomplishments for Regeneron as we further diversified our revenue base and made important progress in our robust R&D pipeline, said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron.
• In 2024, we plan to build on this momentum with continued growth of our breakthrough products Dupixent and EYLEA HD while we bring additional new therapies to market and advance our growing pipeline.
• We were pleased with our fourth-quarter and full-year 2023 financial performance, highlighted by revenue growth of 14% and 12%, respectively, when excluding contributions from Ronapreve, reflecting continued strength across our business, said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.
• In 2024, we plan to continue investing heavily in internal R&D, driving commercial execution with targeted promotion, and prudently deploying capital to business development and share repurchases, all of which is expected to better position the Company to deliver sustainable growth and long-term value to shareholders.

Industry Context

Regeneron's results reflect the ongoing growth in the biotechnology sector, particularly in areas like immunology and oncology. The company's focus on developing innovative therapies and expanding indications for existing products aligns with industry trends. The acquisition of 2seventy bio's cell therapy pipeline also indicates a strategic move towards emerging therapeutic modalities.

Comparison to Industry Standards

• Regeneron's 14% revenue growth excluding Ronapreve in Q4 is strong compared to some of its peers in the large-cap biotech space, such as Amgen and Gilead, which have seen more modest growth in recent quarters.
• The 31% growth in Dupixent sales is particularly impressive, outpacing many other immunology drugs in the market, and is comparable to the growth seen by some of the leading monoclonal antibody therapies.
• The launch of EYLEA HD and its initial sales of $123 million in Q4 indicate a successful product launch, which is a key metric for biotech companies. This compares favorably to the launch of other new ophthalmic drugs.
• The 50% growth in Libtayo sales is also notable, demonstrating the company's success in the oncology space, and is comparable to the growth of other checkpoint inhibitors in the market.
• The company's R&D spending is high, reflecting its commitment to innovation, which is a common trait among leading biotech companies like Vertex and BioMarin.

Management Changes

Legal Proceedings

• The company is involved in a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. concerning Mylan's filing for FDA approval of an aflibercept 2 mg biosimilar. The court found that certain claims of Regeneron's formulation patent were valid and infringed, while certain claims of its methods of treatment patents were infringed but invalid as obvious.

Stakeholder Impact

• Shareholders may be impacted by the mixed financial results and the company's future performance.
• Employees may be impacted by the company's ongoing R&D investments and strategic acquisitions.
• Patients may benefit from the company's development of new therapies and expanded indications for existing products.
• Customers may be impacted by the availability and pricing of the company's products.
• Suppliers and creditors may be impacted by the company's financial performance and strategic decisions.

Next Steps

• Initiate pivotal retinal vein occlusion (RVO) study of EYLEA HD (mid-2024).
• Initiate pivotal studies of pozelimab in combination with cemdisiran in geographic atrophy (second half 2024).
• EC decision on regulatory submission for Dupixent for EoE in children (second half 2024).
• sBLA acceptance for Dupixent in COPD (first quarter 2024) and FDA decision on sBLA (mid/second half 2024); EC decision on regulatory submission (second half 2024).
• Report results from ongoing Phase 3 study for Dupixent in chronic spontaneous urticaria (CSU) (fourth quarter 2024).
• Initiate Phase 1 study in severe food allergy following transient linvoseltamab treatment (in combination with Dupixent) (2024).
• Complete enrollment of Phase 3 studies of itepekimab in COPD (second half 2024).
• Conduct interim analysis from Phase 3 study of Libtayo in adjuvant cutaneous squamous cell carcinoma (CSCC) (second half 2024).
• Report potentially pivotal initial results from Phase 2/3 study of fianlimab in combination with Libtayo in first-line metastatic melanoma and initial combination data in first-line advanced non-small cell lung cancer (NSCLC) (second half 2024).
• Initiate potentially pivotal Phase 2 study for fianlimab (in combination with Libtayo) in perioperative melanoma and Phase 2 study for fianlimab (in combination with Libtayo) in perioperative NSCLC (first half 2024).
• Initiate dose-expansion cohorts of REGN7075 in combination with Libtayo in EGFR-high tumors (first half 2024).
• Initiate cohorts combining REGN5678 and REGN4336 in metastatic castration-resistant prostate cancer and initiate REGN5678 monotherapy cohort in renal cell carcinoma (first half 2024).
• FDA decision on BLA (target action date of March 31, 2024) and EC decision on regulatory submission (second half 2024) for odronextamab in relapsed/refractory FL and DLBCL.
• BLA acceptance for linvoseltamab in relapsed/refractory multiple myeloma (first quarter 2024) and FDA decision on BLA (second half 2024).
• Initiate Phase 1 study of linvoseltamab in combination with CD38 and CD28 costimulatory bispecific antibody in multiple myeloma (2024).
• Report Phase 2 results for REGN9933 in thrombosis (second half 2024).
• Initiate Phase 1 study of Factor 9 gene insertion in hemophilia B (mid-2024).
• Report additional data from Phase 1/2 study for DB-OTO in pediatrics with hearing loss (2024).
• Initiate Phase 1 study of ALN-SOD in amyotrophic lateral sclerosis (ALS) (2024).
• Initiate Phase 2 study of semaglutide in combination with trevogrumab with and without garetosmab (mid-2024).

Key Dates

Keywords

Regeneron, Pharmaceuticals, Dupixent, EYLEA, Libtayo, Revenue, Clinical Trials, FDA, Regulatory Approval, Pipeline, Acquisition, Oncology, Immunology